Piboserod

Piboserod

Systematic (IUPAC) name
N-((1-Butyl-4-piperidyl)-methyl)-3,4-dihydro-2H-(1,3)oxazino(3,2-a)indole-10-carboxamide
Clinical data
Routes of administration	Oral
Legal status	Clinical phase II
Identifiers
CAS Number	152811-62-6
ATC code	none
PubChem	CID 177336
IUPHAR/BPS	225
ChemSpider	154413
UNII	4UQ3S81B25
ChEMBL	CHEMBL356359
Chemical data
Formula	C22H31N3O2
Molar mass	369.50 g/mol
SMILES CCCCN1CCC(CC1)CNC(=O)C2=C3N(CCCO3)C4=CC=CC=C42
InChI InChI=1S/C22H31N3O2/c1-2-3-11-24-13-9-17(10-14-24)16-23-21(26)20-18-7-4-5-8-19(18)25-12-6-15-27-22(20)25/h4-5,7-8,17H,2-3,6,9-16H2,1H3,(H,23,26) Key:KVCSJPATKXABRQ-UHFFFAOYSA-N
(what is this?)  (verify)

Piboserod is a selective 5-HT₄ receptor antagonist which was marketed and manufactured by GlaxoSmithKline (GSK) under the trade name Serlipet for the management of atrial fibrillation and irritable bowel syndrome. In 2007 the Norwegian company Bio-Medisinsk Innovasjon AS (BMI)^[1] completed a clinical phase II study to investigate the effect of piboserod in patients with chronic heart failure.

Mechanism of action

In 2002 a research group at the University of Oslo discovered that muscles from the ventricle of failing hearts have increased responsiveness to serotonin.^[2] They later demonstrated that the effect was due to an expression of functional 5-HT₄ receptors in the failing muscle. On the basis of these findings, and in analogy with the success of betablockers in heart failure, the group made the hypothesis that 5-HT₄ receptor antagonists could be useful to treat heart failure. Their hypothesis was tested in animal models of heart failure with positive results.^[3]

References

1. Company web-page
2. Bratteli, T.; et al. (2004). "Functional serotonin 5-HT4 receptors in porcine and human ventricular myocardium with increased 5-HT4 mRNA in heart failure. Naunyn-Schmiedeberg's". Arch. Pharmacol. 370: 157–166. doi:10.1007/s00210-004-0963-0.
3. Birkeland, JA.; et al. (Jan 2007). "Effects of treatment with a 5-HT4 receptor antagonist in heart failure". Br J Pharmacol 150 (2): 143–52. doi:10.1038/sj.bjp.0706966.